Patent Approval for ATR-12#

Azitra Inc., based in Branford, Connecticut, has been granted a U.S. patent for its lead product candidate, ATR-12, aimed at treating Netherton syndrome. The patent, numbered 12,606,610 B2, was issued on April 21, 2026. It covers specific microbes that produce parts of a protein known as the lympho-epithelial Kazal-type-related inhibitor (LEKTI), which is crucial for treating skin diseases, including Netherton syndrome.

Current Market Position#

As of now, Azitra's stock is trading at $0.25, giving the company a market capitalization of approximately $3.99 million. Over the past year, the stock has seen a significant decline of 87%. Despite this downturn, the shares are currently valued below some estimates of their fair value, which may indicate potential for recovery as the company advances its clinical programs.

Clinical Trials and Financial Health#

ATR-12 employs a modified strain of the bacteria S. epidermidis to deliver a fragment of the human LEKTI protein. Azitra is in the process of conducting a Phase 1b clinical trial to evaluate ATR-12 for treating Netherton syndrome, a chronic skin condition that affects around 20,000 patients worldwide. Currently, there are no approved therapies for this condition.

Azitra is also facing financial challenges, with a negative free cash flow of $11.25 million. Analysts predict ongoing losses, with an earnings per share forecast of -$0.90 for fiscal 2026. The company is set to report its earnings on May 7, 2026.

Additional Developments#

In addition to ATR-12, Azitra is developing another treatment, ATR-04, which targets rashes associated with EGFR inhibitors, affecting about 150,000 individuals in the U.S. This program has received Fast Track designation from the FDA. Recently, Azitra announced a financial boost of up to $31.4 million through a securities purchase agreement with institutional investors, which will help support its ongoing projects. However, the company has also received a warning from NYSE American regarding potential delisting due to not meeting equity standards.